Compare PKE & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | ENTA |
|---|---|---|
| Founded | 1954 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.4M | 486.3M |
| IPO Year | N/A | 2013 |
| Metric | PKE | ENTA |
|---|---|---|
| Price | $21.41 | $15.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | 105.3K | ★ 370.9K |
| Earning Date | 01-15-2026 | 02-09-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 5.81 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | $63,128,000.00 | ★ $65,324,000.00 |
| Revenue This Year | N/A | $0.99 |
| Revenue Next Year | N/A | $0.19 |
| P/E Ratio | $60.01 | ★ N/A |
| Revenue Growth | ★ 7.63 | N/A |
| 52 Week Low | $11.97 | $4.09 |
| 52 Week High | $22.55 | $17.15 |
| Indicator | PKE | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 60.34 | 60.04 |
| Support Level | $20.98 | $14.07 |
| Resistance Level | $22.55 | $17.15 |
| Average True Range (ATR) | 0.84 | 0.95 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 57.20 | 56.71 |
Park Aerospace Corp designs is an aerospace company which develops and manufactures solution and hot-melt composite materials used to produce composite structures for the aerospace markets. Its composite materials include film adhesives and lightning strike protection materials. Its composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as drones), business jets, general aviation aircraft and rotary wing aircraft. The Company's products are sold to customers in North America, Asia and Europe.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.